Gene Expression Profiling and Response Signatures Associated With Differential Responses to Infliximab Treatment in Ulcerative Colitis

Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis

(2010) Matthias Jürgens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

(2009) I. Arijs et al.   GUT

Importance of mucosal healing in ulcerative colitis

(2009) Gary R. Lichtenstein et al.   INFLAMMATORY BOWEL DISEASES

Interleukin-23 and Th17 Cells in the Control of Gut Inflammation

(2009) Ivan Monteleone et al.   MEDIATORS OF INFLAMMATION

Infliximab therapy decreases the levels of TNF-α and IFN-γ mRNA in colonic mucosa of ulcerative colitis

(2009) Trine Olsen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

The role of the novel Th17 cytokine IL-26 in intestinal inflammation

(2008) J Dambacher et al.   GUT

Mucosal cytokine network in inflammatory bowel disease

(2008) Akira Andoh et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Linking genetic susceptibility to Crohnʼs disease with Th17 cell function: IL-22 serum levels are increased in Crohnʼs disease and correlate with disease activity and IL23R genotype status

(2007) Silke Schmechel et al.   INFLAMMATORY BOWEL DISEASES

Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): Upregulated colonic IL-17F expression in active Crohnʼs disease and analysis of the IL17F p.His161Arg polymorphism in IBD

(2007) Julia Seiderer et al.   INFLAMMATORY BOWEL DISEASES